Volume 13 Issue 3
May  2022
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2022  >  13(3): 356-362
Zhang Jie, Cheng Fumin, Zhu Kunlun, et al. Exposure difference of various dosage forms of mycophenolic acid in different age groups of pediatric kidney transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(3): 356-362. doi: 10.3969/j.issn.1674-7445.2022.03.012
Citation: Zhang Jie, Cheng Fumin, Zhu Kunlun, et al. Exposure difference of various dosage forms of mycophenolic acid in different age groups of pediatric kidney transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(3): 356-362. doi: 10.3969/j.issn.1674-7445.2022.03.012
shu

Exposure difference of various dosage forms of mycophenolic acid in different age groups of pediatric kidney transplantation

doi: 10.3969/j.issn.1674-7445.2022.03.012

  • Department of Kidney Transplantation, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

More Information
  • Corresponding author: Feng Guiwen, Email: fengguiwen@zzu.edu.cn
  • Received Date: 2022-02-01
    Available Online: 2022-04-29
  • Publish Date: 2022-05-15
    Abstract
  •   Objective  To investigate the exposure difference of different dosage forms of mycophenolic acid (MPA) between children aged ≤12 and > 12 years old after kidney transplantation.  Methods  Clinical data of 73 children undergoing kidney transplantation from donation after cardiac death (DCD) were retrospectively analyzed. Postoperative immunosuppressive regimen was MPA+ tacrolimus+glucocorticoid. According to different dosage forms of MPA, all recipients were divided into group A (n=37, mycophenolate mofetil capsules), group B (n=28, enteric-coated mycophenolate sodium) and group C (n=8, mycophenolate mofetil dispersible tablets). All children were divided into ≤12 and > 12 years old groups according to the age of kidney transplantation. The daily dosage of different dosage forms was calculated. The blood concentration (C) of MPA and the area under the curve (AUC) were detected by enzyme-multiplied immunoassay technique. The MPA blood concentration was statistically compared between two age groups at different time points. The recovery of renal function and postoperative complications were assessed.  Results  No significant differences were observed in the dosage and blood concentration of drug at different time points among groups A, B and C (all P > 0.05). The MPA-C4 h and AUC in the ≤12 years old group were significantly higher than those in the > 12 years old group (both P < 0.05). In group B, the MPA-C4 h of children aged ≤12 years old was significantly higher compared with that in those aged > 12 years old (P=0.016). The MPA-C4 h of children aged ≤12 years old in group B was higher than those in group A and group C, but the differences were not statistically significant (P=0.080). There was no significant difference in the incidence of acute rejection and infection among three groups (both P > 0.05).  Conclusions  Children of different ages who are given with different dosage forms of MPA after kidney transplantation obtain different exposure rates. The exposure rate of kidney transplant recipients aged ≤12 years old tends to be higher than that of their counterparts aged > 12 years old, mainly seen in the recipients treated with enteric-coated mycophenolate sodium. Therefore, it is necessary to monitor the exposure level of MPA, which provides significant guidance for adjusting the drug dosage of different dosage forms.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    HART A, SMITH JM, SKEANS MA, et al. OPTN/SRTR 2016 annual data report: kidney[J]. Am J Transplant, 2018, 18(Suppl 1): 18-113. DOI: 10.1111/ajt.14557.
    [2]
    BENJANUWATTRA J, PRUKSAKORN D, KOONRUNGSESOMBOON N. Mycophenolic acid and its pharmacokinetic drug-drug interactions in humans: review of the evidence and clinical implications[J]. J Clin Pharmacol, 2020, 60(3): 295-311. DOI: 10.1002/jcph.1565.
    [3]
    曹懿睿, 贾亦臣. 霉酚酸类药物在器官移植受者中的药代动力学研究进展[J]. 器官移植, 2020, 11(5): 635-645. DOI: 10.3969/j.issn.1674-7445.2020.05.018.

    CAO YR, JIA YC. Research progress on pharmacokinetics of mycophenolic acid drugs in organ transplant recipients[J]. Organ Transplant, 2020, 11(5): 635-645. DOI: 10.3969/j.issn.1674-7445.2020.05.018.
    [4]
    FILLER G, ALVAREZ-ELÍAS AC, MCINTYRE C, et al. The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy[J]. Pediatr Nephrol, 2017, 32(1): 21-29. DOI: 10.1007/s00467-016-3352-2.
    [5]
    BRAZEAU D, MEANEY CJ, CONSIGLIO JD, et al. Association of ABCC2 haplotypes to mycophenolic acid pharmacokinetics in stable kidney transplant recipients[J]. J Clin Pharmacol, 2021, 61(12): 1592-1605. DOI: 10.1002/jcph.1932.
    [6]
    BERGAN S, BRUNET M, HESSELINK DA, et al. Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology[J]. Ther Drug Monit, 2021, 43(2): 150-200. DOI: 10.1097/FTD.0000000000000871.
    [7]
    GUO M, WANG ZJ, YANG HW, et al. Influence of genetic polymorphisms on mycophenolic acid pharmacokinetics and patient outcomes in renal transplantation[J]. Curr Drug Metab, 2018, 19(14): 1199-1205. DOI: 10.2174/1389200219666171227201608.
    [8]
    YOO EC, ALVAREZ-ELÍAS AC, TODOROVA EK, et al. Developmental changes of MPA exposure in children[J]. Pediatr Nephrol, 2016, 31(6): 975-982. DOI: 10.1007/s00467-015-3303-3.
    [9]
    BUDDE K, GLANDER P, KRÄMER BK, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes[J]. Transplantation, 2007, 83(4): 417-424. DOI: 10.1097/01.tp.0000251969.72691.ea.
    [10]
    SOBIAK J, RESZTAK M. A systematic review of multiple linear regression-based limited sampling strategies for mycophenolic acid area under the concentration-time curve estimation[J]. Eur J Drug Metab Pharmacokinet, 2021, 46(6): 721-742. DOI: 10.1007/s13318-021-00713-0.
    [11]
    BROOKS EK, TETT SE, ISBEL NM, et al. Evaluation of multiple linear regression-based limited sampling strategies for enteric-coated mycophenolate sodium in adult kidney transplant recipients[J]. Ther Drug Monit, 2018, 40(2): 195-201. DOI: 10.1097/FTD.0000000000000486.
    [12]
    BAUER AC, FRANCO RF, MANFRO RC. Immunosuppression in kidney transplantation: state of the art and current protocols[J]. Curr Pharm Des, 2020, 26(28): 3440-3450. DOI: 10.2174/1381612826666200521142448.
    [13]
    TETT SE, SAINT-MARCOUX F, STAATZ CE, et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure[J]. Transplant Rev (Orlando), 2011, 25(2): 47-57. DOI: 10.1016/j.trre.2010.06.001.
    [14]
    FERREIRA PCL, THIESEN FV, PEREIRA AG, et al. A short overview on mycophenolic acid pharmacology and pharmacokinetics[J]. Clin Transplant, 2020, 34(8): e13997. DOI: 10.1111/ctr.13997.
    [15]
    曾维胜, 张长升, 宋秘, 等. 吗替麦考酚酯与麦考酚钠肠溶片对肾移植受体血药浓度的影响[J]. 器官移植, 2018, 9(6): 436-440. DOI: 10.3969/j.issn.1674-7445.2018.06.007.

    ZENG WS, ZHANG CS, SONG M, et al. Effect of mycophenolate mofetil and enteric-coated mycophenolate sodium on blood concentration in renal transplantrecipients[J]. Organ Transplant, 2018, 9(6): 436-440. DOI: 10.3969/j.issn.1674-7445.2018.06.007.
    [16]
    王娟, 王丽彬, 郭苗, 等. 霉酚酸在肾移植患者中有限采样法监测方案的探讨[J]. 药学与临床研究, 2019, 27(6): 445-448.

    WANG J, WANG LB, GUO M, et al. Investigation on monitoring scheme of mycophenolic acid in renal transplant recipients by limited sampling methods[J]. Pharm Clin Res, 2019, 27(6): 445-448.
    [17]
    RONG Y, JUN H, KIANG TKL. Population pharmacokinetics of mycophenolic acid in paediatric patients[J]. Br J Clin Pharmacol, 2021, 87(4): 1730-1757. DOI: 10.1111/bcp.14590.
    [18]
    ZHANG HX, SHENG CC, LIU LS, et al. Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus[J]. Br J Clin Pharmacol, 2019, 85(4): 746-761. DOI: 10.1111/bcp.13850.
    [19]
    RESZTAK M, SOBIAK J, CZYRSKI A. Recent advances in therapeutic drug monitoring of voriconazole, mycophenolic acid, and vancomycin: a literature review of pediatric studies[J]. Pharmaceutics, 2021, 13(12): 1991. DOI: 10.3390/pharmaceutics13121991.
    [20]
    刘爽, 张恩瑶, 易湛苗, 等. 中国霉酚酸治疗药物监测的现状分析[J]. 中国临床药理学杂志, 2021, 37(3): 308-311. DOI: 10.13699/j.cnki.1001-6821.2021.03.025.

    LIU S, ZHANG EY, YI ZM, et al. Analysis for the current status of mycophenolic acid therapeutic drug monitoring in China[J]. Chin J Clin Pharmacol, 2021, 37(3): 308-311. DOI: 10.13699/j.cnki.1001-6821.2021.03.025.
    [21]
    杨青彦, 王长安, 韩健乐, 等. 霉酚酸浓度监测对肾移植受者移植后感染的预测价值分析[J]. 医药论坛杂志, 2020, 41(11): 81-84.

    YANG QY, WANG CA, HAN JL, et al. Predictive value of mycophenolic acid concentration monitoring in renal transplant recipients after transplantation[J]. J Med Forum, 2020, 41(11): 81-84.
    [22]
    CHAKRABARTI K, FRAME D, AL ABBAS M, et al. The use of mycophenolate mofetil area under the curve[J]. Curr Opin Rheumatol, 2021, 33(3): 221-232. DOI: 10.1097/BOR.0000000000000799.
    [23]
    郑晓洁, 李思泽, 袁雅文, 等. 儿童生理药代动力学模型及其在儿科药物研究中的应用[J]. 药学学报, 2020, 55(1): 38-44. DOI: 10.16438/j.0513-4870.2019-0594.

    ZHENG XJ, LI SZ, YUAN YW, et al. Physiologically based pharmacokinetic modeling for children and its application in pediatric drug research[J]. Acta Pharm Sin, 2020, 55(1): 38-44. DOI: 10.16438/j.0513-4870.2019-0594.
    [24]
    LIM SY, PETTIT RS. Pharmacokinetic considerations in pediatric pharmacotherapy[J]. Am J Health Syst Pharm, 2019, 76(19): 1472-1480. DOI: 10.1093/ajhp/zxz161.
    [25]
    FUKUDA T, GOEBEL J, COX S, et al. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients[J]. Ther Drug Monit, 2012, 34(6): 671-679. DOI: 10.1097/FTD.0b013e3182708f84.
    [26]
    JOHNSON TN, TANNER MS, TAYLOR CJ, et al. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis[J]. Br J Clin Pharmacol, 2001, 51(5): 451-460. DOI: 10.1046/j.1365-2125.2001.01370.x.
    [27]
    KRALL P, YAÑEZ D, ROJO A, et al. CYP3A5 and UGT1A9 polymorphisms influence immunosuppressive therapy in pediatric kidney transplant recipients[J]. Front Pharmacol, 2021, 12: 653525. DOI: 10.3389/fphar.2021.653525.
    [28]
    SCHIAVONE S, NERI M, POMARA C, et al. Personalized medicine in the paediatric population: the balance between pharmacogenetic progress and bioethics[J]. Curr Pharm Biotechnol, 2017, 18(3): 253-262. DOI: 10.2174/1389201018666170207130236.
    [29]
    DE WINTER BC, MATHOT RA, SOMBOGAARD F, et al. Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring[J]. Clin J Am Soc Nephrol, 2011, 6(3): 656-663. DOI: 10.2215/CJN.05440610.
    [30]
    HEBERT SA, SWINFORD RD, HALL DR, et al. Special considerations in pediatric kidney transplantation[J]. Adv Chronic Kidney Dis, 2017, 24(6): 398-404. DOI: 10.1053/j.ackd.2017.09.009.
    [31]
    SCHIJVENS AM, DE WILDT SN, SCHREUDER MF. Pharmacokinetics in children with chronic kidney disease[J]. Pediatr Nephrol, 2020, 35(7): 1153-1172. DOI: 10.1007/s00467-019-04304-9.
    [32]
    BERGER I, HAUBRICH K, ENSOM MHH, et al. RELATE: relationship of limited sampling strategy and adverse effects of mycophenolate mofetil in pediatric renal transplant patients[J]. Pediatr Transplant, 2019, 23(2): e13355. DOI: 10.1111/petr.13355.
    [33]
    EHREN R, SCHIJVENS AM, HACKL A, et al. Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion[J]. Expert Opin Drug Metab Toxicol, 2021, 17(2): 201-213. DOI: 10.1080/17425255.2021.1843633.
    [34]
    邵琨, 陆佳倩, 安会敏, 等. 有限采样法估算中国肾移植受者霉酚酸体内暴露[J]. 中国药师, 2018, 21(9): 1522-1527, 1530. DOI: 10.3969/j.issn.1008-049X.2018.09.004.

    SHAO K, LU JQ, AN HM, et al. Exposure estimation of mycophenolic acid in Chinese renal transplant recipients by limited sampling strategy[J]. China Pharm, 2018, 21(9): 1522-1527, 1530. DOI: 10.3969/j.issn.1008-049X.2018.09.004.
    [35]
    张丽娟, 陈璐, 朱宇轩, 等. 有限采样法用于肾移植受者霉酚酸酯血药浓度监测的分析[J]. 中国生化药物杂志, 2016, 36(7): 187-190. DOI: 10.3969/j.issn.1005-1678.2016.07.57.

    ZHANG LJ, CHEN L, ZHU YX, et al. Use of limited sampling strategy to analyse MMF blood concentration in renal transplant recipients[J]. Chin J Biochem Pharma, 2016, 36(7): 187-190. DOI: 10.3969/j.issn.1005-1678.2016.07.57.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (317) PDF downloads(95) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return